The Food and Drug Administration intends to comply with a measure that would allow patients with terminal ailments the right to access drug candidates not yet approved by the FDA, according to a Fierce Healthcare report. FDA Commissioner Dr. Scott Gottlieb said the agency would ensure patients would be protected under the right-to-try legislation, which passed the U.S. House on May 22.
“I think some of those things we can address through the implementation process while making sure we stay still staying true to the letter of the law,” Gottlieb was quoted as saying in the report. “I think there are things we can do to make sure patients are adequately protected under this legislation while we make sure the goals are achieved.”
The measure, which initially passed the Senate last August, now moves on to President Donald Trump for passage into law.